The BODE index predicted death in chronic obstructive pulmonary disease


Question
In patients with chronic obstructive pulmonary disease (COPD), how well does an index comprising the risk factors that reflect the respiratory, perceptible, and systemic aspects of the disease predict outcome?

Methods
Design: 2 cohort studies, 1 for development and 1 for validation.
Patients: 832 patients (mean age 66 y) who had COPD with a wide range of severity, were in clinically stable condition, and were receiving appropriate therapy. Exclusion criteria were probability of death within 3 years from a cause other than COPD, asthma, inability to take the lung-function and 6-minute walk tests, myocardial infarction within the previous 4 months, unstable angina, or congestive heart failure. 207 patients were recruited from 1995 to 1997 and formed the development cohort; 625 patients were recruited from 1997 to 2003 and formed the validation cohort.

Description of prediction guide: The following variables were assessed for each patient in the development cohort: age, sex, pack-years of smoking, FVC, FEV1, the best of two 6-minute walk tests done 30 minutes apart, degree of dyspnea, body mass index (BMI), functional residual and inspiratory capacities, hematocrit and albumin levels, and degree of comorbid conditions. A logistic regression analysis determined the variables with the strongest association with 1-year mortality. 4 such variables (BMI [B], FEV1 as a percentage of the predicted value as an indication of airflow obstruction [O], score on the modified Medical Research Council [MMRC] dyspnea scale [D], and the distance walked in 6 minutes as an indication of exercise capacity [E]) were included in the BODE index (0 to 10 points). Patients in the validation cohort were seen every 3 to 6 months for ≥ 2 years or until death.

Outcomes: Death from any cause and death from respiratory causes.

Main results
Higher BODE scores were associated with greater risk for death (Table). In a model containing FEV1 or the BODE score as the independent variable, the $c$ statistic for the ability to predict risk for death was greater for the BODE index than for FEV1 (0.74 vs 0.65).

Conclusion
In patients with chronic obstructive pulmonary disease, an index comprising measures of body mass index, degree of airflow obstruction and dyspnea, and exercise capacity predicted all-cause mortality and death from respiratory causes.

Source of funding: No external funding.

For correspondence: Dr. B.R. Celli, St. Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, MA, USA. E-mail bcelli@copdnet.org.

BODE index for predicting death in chronic obstructive pulmonary disease*  

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Hazard ratio (95% CI)</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death from all causes</td>
<td>1.34 (1.26 to 1.42)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Death from respiratory causes</td>
<td>1.62 (1.48 to 1.77)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

*BODE = body-mass index, airflow obstruction, dyspnea, and exercise capacity.
†The hazard ratio is for each 1-point increase in the BODE score.

New evidence-based guidelines for COPD emphasize early disease identification and stratification, using office spirometry. This facilitates implementation of exciting new long-acting inhaled bronchodilators, pulmonary rehabilitation, oxygen treatment, and volume reduction surgery.

The BODE index adds another dimension to this effort by identifying at-risk patients, who are most in need of our interventions. It goes beyond FEV1 alone, using easily implemented office tools: the MMRC dyspnea index (1, 2), 6-minute walk, and BMI as a measure of cachexia (3). It also encourages nonpulmonologists, who care for 80% of these patients, to obtain office spirometry and help identify those who are undiagnosed.

Joseph A. Golish, MD
Cleveland Clinic Foundation
Cleveland, Ohio, USA

References